Skip to content
Inciteful Med

Survivorship & Monitoring: Life After Treatment

Last updated:

After completing schistosomiasis treatment, you must take a follow-up test 4 to 6 weeks later to confirm the parasite is gone. You may also need liver or bladder ultrasounds to monitor for organ healing, as treatment can often reverse internal scarring. Avoid freshwater to prevent reinfection.

Key Takeaways

  • • Follow-up testing is required 4 to 6 weeks after finishing medication to confirm the infection is cured.
  • • Finding dead eggs in your urine or stool after treatment is normal and does not mean the medication failed.
  • • Organ damage, such as liver scarring or bladder wall thickening, can often improve or reverse after successful treatment.
  • • Having schistosomiasis once does not provide immunity, making it crucial to avoid contaminated freshwater to prevent reinfection.

Completing your treatment for schistosomiasis is a major milestone, but your care doesn’t end with the last pill. Survivorship involves a clear plan to confirm the infection is gone, monitoring your organs for healing, and taking steps to stay healthy in the future [1][2].

Confirming the Cure: The Retesting Timeline

It is essential to verify that the medication successfully cleared the parasites from your body. Because the parasite has a complex life cycle, testing too early can give a false sense of security.

  • The 4-to-6 Week Rule: Most doctors recommend a follow-up test 4 to 6 weeks after you finish treatment [3][4]. This timing is important because it allows enough time for the parasite antigens (proteins) to clear from your blood and for any surviving worms to be detected [5][4].
  • Choice of Test: While traditional microscopy (looking for eggs) is common, newer antigen tests (like CAA or CCA) or DNA tests (PCR) are often more sensitive at finding “hidden” or low-level infections that might remain after treatment [6][7].
  • Dead Eggs vs. Live Eggs: Be aware that dead parasite eggs can sometimes continue to be excreted in your urine or stool for weeks or even months after a successful cure. Your doctor will specifically check for live eggs to determine if the treatment worked; finding dead eggs does not mean the treatment failed [8][9].

Monitoring Your Organs: Imaging and Follow-Up

If your infection was chronic (lasting a long time before treatment), your doctor may want to monitor your organs for scarring or inflammation.

  • Liver Monitoring: For intestinal schistosomiasis, an ultrasound is the gold-standard tool to check for periportal fibrosis (scarring around the liver’s veins) [10][11]. The good news is that this scarring can often improve or even reverse after successful treatment, especially if caught early [12][13].
  • Bladder Monitoring: For urogenital schistosomiasis, an ultrasound can identify bladder wall thickening [14]. In many cases—especially in younger patients—these bladder changes can resolve completely within six months after treatment [14][15].
  • Long-Term Surveillance: While there is no “one-size-fits-all” schedule, patients with significant scarring may need periodic imaging every 6 to 12 months to monitor their progress.

Preventing Reinfection

Unfortunately, having schistosomiasis once does not make you immune to getting it again [16]. If you live in or travel back to an endemic area, prevention is key:

  1. Avoid Contaminated Freshwater: The most effective strategy is to avoid swimming, wading, or bathing in freshwater lakes, rivers, or streams where the parasite is known to live [1][17].
  2. Safe Water Use: Use “safe” water for drinking and washing. Standard chemical treatments (like iodine or chlorine tablets) do not reliably kill the parasite larvae. To ensure water is safe for bathing, the CDC recommends heating the water to 150°F (65°C) for 5 minutes, or allowing it to stand in a storage tank for at least 48 to 72 hours before use [18].
  3. Vigilance: If you must enter the water (for work or necessary travel), wearing protective gear like rubber boots can reduce skin exposure, though total avoidance is always safer [19].

Coping with “Survivorship Anxiety”

It is normal to feel anxious about the possibility of long-term organ damage or reinfection [20].

  • Uncertainty is common: Because protocols for chronic management can vary between doctors, you may feel like you aren’t getting a clear answer [21].
  • Focus on the facts: Remember that schistosomiasis is a treatable condition, and modern imaging can catch complications early when they are most manageable [1][10].
  • Empower yourself with education: Understanding the transmission cycle and staying up-to-date with your follow-up appointments can help you regain a sense of control over your health [22].

Frequently Asked Questions

When should I get retested after schistosomiasis treatment?
Most doctors recommend a follow-up test 4 to 6 weeks after you finish your medication. This timeline ensures any surviving worms are detected while allowing old parasite proteins to clear from your blood.
Does finding parasite eggs in my stool after treatment mean I am still infected?
Not necessarily. Dead parasite eggs can continue to be excreted in your urine or stool for months after a successful cure. Your doctor will specifically check for live eggs to determine if the treatment worked.
Will the liver or bladder damage from schistosomiasis go away?
Often, yes. Scarring around the liver or thickening of the bladder wall can improve or even completely reverse after successful treatment, especially if caught early and monitored with regular ultrasounds.
Can I become immune to schistosomiasis after having it once?
No, having schistosomiasis does not make you immune to future infections. If you return to an area where the parasite lives, you must take precautions like avoiding contaminated freshwater to prevent getting infected again.

Questions for Your Doctor

  • • When exactly should I come back for my follow-up stool or urine test to confirm the treatment worked?
  • • Which test is best for my follow-up: the traditional microscopy or a more sensitive antigen/DNA test?
  • • Based on my initial infection level, do I need a follow-up ultrasound of my liver or bladder, and if so, how often?
  • • Is the scarring (fibrosis) found on my imaging likely to improve over time now that I've been treated?
  • • What specific activities should I avoid if I return to a region where schistosomiasis is common?
  • • Should we schedule my follow-up stool/urine test now?

Questions for You

  • • Do I have a copy of my treatment records, including the specific dose of praziquantel I received?
  • • Am I still feeling the same level of fatigue or pain as before treatment, or has it started to improve?
  • • What steps can I take to ensure my family or travel companions are also screened if they shared the same water exposure?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Schistosomiasis.

    McManus DP, Dunne DW, Sacko M, et al.

    Nature reviews. Disease primers 2018; (4(1)):13 doi:10.1038/s41572-018-0013-8.

    PMID: 30093684
  2. 2

    Outbreak of Schistosomiasis mansoni in a Spanish dance and percussion ensemble acquired in the Republic of Guinea.

    Arsuaga Vicente M, Ruiz-Carrascoso G, De la Calle-Prieto F, et al.

    Enfermedades infecciosas y microbiologia clinica (English ed.) 2025; (43(9)):571-576 doi:10.1016/j.eimce.2025.01.011.

    PMID: 40410036
  3. 3

    Efficacy of Single-Dose Praziquantel for the Treatment of Schistosoma mansoni Infections among School Children in Rwanda.

    Kabatende J, Ntirenganya L, Mugisha M, et al.

    Pathogens (Basel, Switzerland) 2023; (12(9)) doi:10.3390/pathogens12091170.

    PMID: 37764978
  4. 4

    Performance of an Ultra-Sensitive Assay Targeting the Circulating Anodic Antigen (CAA) for Detection of Schistosoma mansoni Infection in a Low Endemic Area in Brazil.

    Sousa MS, van Dam GJ, Pinheiro MCC, et al.

    Frontiers in immunology 2019; (10()):682 doi:10.3389/fimmu.2019.00682.

    PMID: 31019510
  5. 5

    Rapid clearance of Schistosoma mansoni circulating cathodic antigen after treatment shown by urine strip tests in a Ugandan fishing community - Relevance for monitoring treatment efficacy and re-infection.

    Kildemoes AO, Vennervald BJ, Tukahebwa EM, et al.

    PLoS neglected tropical diseases 2017; (11(11)):e0006054 doi:10.1371/journal.pntd.0006054.

    PMID: 29131820
  6. 6

    Limited efficacy of repeated praziquantel treatment in Schistosoma mansoni infections as revealed by highly accurate diagnostics, PCR and UCP-LF CAA (RePST trial).

    Hoekstra PT, Casacuberta-Partal M, van Lieshout L, et al.

    PLoS neglected tropical diseases 2022; (16(12)):e0011008 doi:10.1371/journal.pntd.0011008.

    PMID: 36548444
  7. 7

    Evaluation of serum-based real-time PCR to detect Schistosoma mansoni infection before and after treatment.

    Fuss A, Mazigo HD, Mueller A

    Infectious diseases of poverty 2020; (9(1)):74 doi:10.1186/s40249-020-00698-z.

    PMID: 32571433
  8. 8

    Insufficiency of annual praziquantel treatment to control Schistosoma mansoni infections in adult women: A longitudinal cohort study in rural Tanzania.

    Mishra P, Colombe S, Paul N, et al.

    PLoS neglected tropical diseases 2019; (13(11)):e0007844 doi:10.1371/journal.pntd.0007844.

    PMID: 31751333
  9. 9

    [Diagnosis and treatment of an imported case of schistosomiasis haematobium].

    Yan-Rong L, Han-Guo X, Zhu-Yun C, et al.

    Zhongguo xue xi chong bing fang zhi za zhi = Chinese journal of schistosomiasis control 2017; (29(1)):108-110 doi:10.16250/j.32.1374.2016240.

    PMID: 29469403
  10. 10

    Ultrasonographic findings in Schistosoma mekongi infection. A minireview.

    Richter J, Kling K, Hatz C, Neumayr A

    Parasitology international 2026; (110()):103138 doi:10.1016/j.parint.2025.103138.

    PMID: 40774376
  11. 11

    The role of point-of-care ultrasound in the assessment of schistosomiasis-induced liver fibrosis: A systematic scoping review.

    Ockenden ES, Frischer SR, Cheng H, et al.

    PLoS neglected tropical diseases 2024; (18(3)):e0012033 doi:10.1371/journal.pntd.0012033.

    PMID: 38507368
  12. 12

    Hepatic schistosomiasis with massive splenomegaly: a case report and literature review.

    Thijs L, Messiaen P, van der Hilst J, et al.

    Acta gastro-enterologica Belgica 2018; (81(1)):93-96.

    PMID: 29562382
  13. 13

    Hepatosplenic Schistosomiasis Presenting as Melena in an Adolescent Filipino Male: A Case Report and Literature Review.

    Torrico JC, Gregorio GEV

    Acta medica Philippina 2025; (59(5)):92-98 doi:10.47895/amp.vi0.9817.

    PMID: 40438486
  14. 14

    Diagnosis and management of complicated urogenital schistosomiasis: a systematic review of the literature.

    Manciulli T, Marangoni D, Salas-Coronas J, et al.

    Infection 2023; (51(5)):1185-1221 doi:10.1007/s15010-023-02060-5.

    PMID: 37466786
  15. 15

    Usefulness of ultrasound in sub-Saharan patients with a serological diagnosis of schistosomiasis.

    Castillo-Fernández N, Soriano-Pérez MJ, Lozano-Serrano AB, et al.

    Infection 2021; (49(5)):919-926 doi:10.1007/s15010-021-01612-x.

    PMID: 33948875
  16. 16

    From treatment to prevention: reimagining schistosomiasis control through WASH and environmental management.

    Adediran MB, Adesida A, Ezekiel OO, et al.

    Pathogens and global health 2025; 1-17 doi:10.1080/20477724.2025.2603235.

    PMID: 41396490
  17. 17

    Impact of Different Mass Drug Administration Strategies for Gaining and Sustaining Control of Schistosoma mansoni and Schistosoma haematobium Infection in Africa.

    King CH, Kittur N, Binder S, et al.

    The American journal of tropical medicine and hygiene 2020; (103(1_Suppl)):14-23.

    PMID: 32400356
  18. 18

    Improving spatial prediction of Schistosoma haematobium prevalence in southern Ghana through new remote sensors and local water access profiles.

    Kulinkina AV, Walz Y, Koch M, et al.

    PLoS neglected tropical diseases 2018; (12(6)):e0006517 doi:10.1371/journal.pntd.0006517.

    PMID: 29864165
  19. 19

    Knowledge, attitudes, and practices regarding schistosomiasis infection and prevention: A mixed-methods study among endemic communities of western Uganda.

    Anyolitho MK, Poels K, Huyse T, et al.

    PLoS neglected tropical diseases 2022; (16(2)):e0010190 doi:10.1371/journal.pntd.0010190.

    PMID: 35196328
  20. 20

    Transjugular intrahepatic portosystemic shunt followed by splenectomy for complicated hepatosplenic schistosomiasis: a case report and review of the literature.

    Tamarozzi F, Ursini T, Stroffolini G, et al.

    The Lancet. Infectious diseases 2024; (24(6)):e405-e414 doi:10.1016/S1473-3099(23)00689-8.

    PMID: 38368890
  21. 21

    High-dose or multi-day praziquantel for imported schistosomiasis? A systematic review.

    Cucchetto G, Buonfrate D, Marchese V, et al.

    Journal of travel medicine 2019; (26(7)) doi:10.1093/jtm/taz050.

    PMID: 31309979
  22. 22

    Exploring healthcare professionals' perspectives on neglected tropical diseases in Eastern Uganda: a qualitative study with a focus on schistosomiasis and soil-transmitted helminths.

    Kihumuro RB, Atimango L, Kintu TM, et al.

    Transactions of the Royal Society of Tropical Medicine and Hygiene 2024; (118(12)):781-789 doi:10.1093/trstmh/trae043.

    PMID: 39115255

This page provides educational information on recovering from schistosomiasis. Always consult your infectious disease specialist or primary care doctor for your specific follow-up testing and imaging schedule.

Stay up to date

Get notified when new research about Schistosomiasis is published.

No spam. Unsubscribe anytime.